

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vrignia 22313-1450 www.uspto.gov

APPLICATION NO.	. F	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/051,765		01/17/2002	Richard J. Fitzpatrick	1932.1110-002	
21005	7590	07/01/2003			
	•	OK, SMITH & RE	EXAMINER		
530 VIRGI P.O. BOX	9133	_	FUBARA, BLESSING M		
CONCORD, MA 01742-9133		742-9133		ART UNIT	PAPER NUMBER
				1615	11
				DATE MAILED: 07/01/2003	17

Please find below and/or attached an Office communication concerning this application or proceeding.

· *								
	Application N .		Applicant(s)	-				
	10/051,765		FITZPATRICK ET AL.					
Office Action Summary	Examiner		Art Unit					
	Blessing M. Fuba		1615					
The MAILING DATE of this communicati n app Period for Reply	ears on the cove	r sheet with the c	rrespondence ad	dress				
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, - Any reply received by the Office later than three months after the mailing eamed patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, howen within the statutory mir vill apply and will expire cause the application to	ever, may a reply be time nimum of thirty (30) days SIX (6) MONTHS from the become ABANDONED	ely filed will be considered timely he mailing date of this co 0 (35 U.S.C. § 133).					
Status								
1) Responsive to communication(s) filed on 14 A				·				
, 	is action is non-fi							
 Since this application is in condition for allowal closed in accordance with the practice under a Disposition of Claims 				e merits is				
4)⊠ Claim(s) <u>1-74</u> is/are pending in the application								
4a) Of the above claim(s) is/are withdraw		ation.						
5) Claim(s) is/are allowed.								
6)⊠ Claim(s) <u>36-41</u> is/are rejected.			·					
7)⊠ Claim(s) <u>42-50</u> is/are objected to.								
8) Claim(s) are subject to restriction and/or	election require	ment.						
Application Papers	·							
9) The specification is objected to by the Examiner	•							
10)☐ The drawing(s) filed on is/are: a)☐ accep	ted or b) object	ed to by the Exam	niner.					
Applicant may not request that any objection to the	e drawing(s) be hel	d in abeyance. Se	e 37 CFR 1.85(a).					
11) The proposed drawing correction filed on	is: a)∏ approve	ed b)∐ disapprov	ed by the Examine	er.				
If approved, corrected drawings are required in rep	ly to this Office ac	tion.						
12) The oath or declaration is objected to by the Exa	aminer.			•				
Priority under 35 U.S.C. §§ 119 and 120								
13) Acknowledgment is made of a claim for foreign	priority under 35	5 U.S.C. § 119(a)	-(d) or (f).					
a) ☐ All b) ☐ Some * c) ☐ None of:								
 Certified copies of the priority documents 	1. Certified copies of the priority documents have been received.							
2. Certified copies of the priority documents	have been rece	ived in Applicatio	n No					
 3. Copies of the certified copies of the prior application from the International Bur * See the attached detailed Office action for a list of the certified copies of the prior application. 	eau (PCT Rule 1	17.2(a)).		Stage				
14) Acknowledgment is made of a claim for domestic		•		application).				
a) ☐ The translation of the foreign language pro- 15)☐ Acknowledgment is made of a claim for domestic	visional application	on has been rece	ived.	,				
Attachment(s)	- Priority under O	2 3.5.5. 33 120						
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 5.6	4)		(PTO-413) Paper No(atent Application (PTC					

Application/Control Number: 10/051,765

Art Unit: 1615

DETAILED ACTION

Examiner acknowledges receipt of declaration and preliminary amendment A filed 05/21/02, IDS filed 10/31/02 and 12/20/02, supplemental amendment filed 03/11/03 and 04/15/03 and amendment B filed 04/14/03.

Information Disclosure Statement

1. The information disclosure statement filed 10/31/02 fails to comply with 37 CFR 1.98(a)(2), which requires a legible copy of each U.S. and foreign patent; each publication or that portion which caused it to be listed; and all other information or that portion which caused it to be listed. It has been placed in the application file, but the information referred to therein has not been considered.

The non-US references cited in the Form PTO-1449 are not available to the examiner to review. Examiner respectfully requests applicants to submit the non-US references.

Election/Restrictions

Applicants elected the polymer that is characterized by the repeat unit having structural formula (VI) and identified claims 36-38, 42-44 and 48-50. Applicants further indicate that pharmaceutical composition claims 39-41 and method claims 45-47 that comprise polymer having the structural formula (VI) be examined with claims 36-38, 42-44 and 48-50. Examiner finds the above request persuasive and thus examines claims 36-50.

Double Patenting

2. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed.

Application/Control Number: 10/051,765

Art Unit: 1615

Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

3. Claims 36-41 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-5, 10, 20-24 of copending Application No. 10/051,766, now published application number US 2003/0021761. Although the conflicting claims are not identical, they are not patentably distinct from each other because the composition used in the co-pending application to treat mucositis comprises the polymer of said claims of the examined application. The co-pending application differs from the instant application in that the claims of the co-pending application are directed to method of treating and the instant claims are directed the polymer and pharmaceutical composition that comprises the polymer. However, the method of the co-pending application utilizes a composition comprising the polymer of the instant application.

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

4. Claims 42-50 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. The prior art does not teach a method of treating microbial infections where the method comprises administering to a subject in need thereof a composition that comprises the polyionene polymer having a repeat unit of structural formula (VI).

Application/Control Number: 10/051,765 Page 4

Art Unit: 1615

5. The lengthy specification has not been checked to the extent necessary to determine the presence of all possible minor errors. Applicants' cooperation is requested in correcting any errors of which applicants may become aware in the specification.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Blessing M. Fubara whose telephone number is 703-308-8374. The examiner can normally be reached on 7 a.m. to 3:30 p.m. (Monday to Friday).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman K. Page can be reached on 703-308-2927. The fax phone numbers for the organization where this application or proceeding is assigned are 703-305-3592 for regular communications and 703-305-3592 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1234.

Blessing Fubara AB Labora

Patent Examiner Tech. Center 1600

June 27, 2003